Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-01-11

FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approves a supplemental application for ADEMPAS (riociguat) submitted by Bayer HealthCare Pharmaceuticals Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adempas (riociguat)

Snippet

SUPPL AP for ADEMPAS (RIOCIGUAT)